A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.

被引：0
|
作者：
Lilly, M
Kuriakose, P
Turturro, F
Berdeja, J
Kerr, R
Surendranathan, A
Black, J
Frankel, A
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
[2] Henry Ford Hosp, Detroit, MI 48202 USA
[3] Louisiana State Univ, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA
[4] SW Reg Canc Ctr, Austin, TX USA
[5] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[6] Wake Forest Univ, Winston Salem, NC 27109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：597S / 597S
页数：1
相关论文
共 50 条
  • [1] A phase II study of denileukin diftitox (ONTAKR) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.
    Kuriakose, P
    Turturro, F
    Berdeja, JG
    Kerr, R
    Surendranathan, A
    Black, J
    Frankel, AE
    BLOOD, 2004, 104 (11) : 289B - 289B
  • [2] A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia
    Frankel, AE
    Fleming, DR
    Hall, PD
    Powell, BL
    Black, JH
    Leftwich, C
    Gartenhaus, R
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3555 - 3561
  • [3] Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer
    Salazar, L. G.
    Higgins, D.
    Childs, J.
    Bates, N.
    Dang, Y.
    Slota, M.
    Coveler, A. L.
    Waisman, J. R.
    Disis, M. L.
    CANCER RESEARCH, 2009, 69 (24) : 750S - 751S
  • [4] Diphtheria fusion protein ONTAK® therapy of patients with fludarabine-refractory chronic lymphocytic leukemia.
    Frankel, A
    Fleming, D
    Gartenhaus, R
    Powell, BL
    Black, JH
    Leftwich, CF
    BLOOD, 2002, 100 (11) : 365B - 366B
  • [5] Phase II study of fludarabine and mitoxantrone in patients with chronic lymphocytic leukemia.
    Tsimberidou, AM
    Keating, MJ
    Giles, F
    Lerner, S
    Kantarjian, HM
    O'Brien, S
    BLOOD, 2003, 102 (11) : 358B - 358B
  • [6] Phase II trial of the diphtheria fusion protein ONTAK in patients with fludarabine refractory chronic lymphocytic leukemia (CLL).
    Frankel, AE
    Patrick, CL
    Powell, BL
    BLOOD, 2001, 98 (11) : 289B - 289B
  • [7] A phase II study of fludarabine (F) and mitoxantrone (N) in the treatment of previously untreated B-cell chronic lymphocytic leukemia.
    Enschede, SH
    Venugopal, P
    Guevarra, AL
    O'Brien, TM
    Gregory, SA
    BLOOD, 2000, 96 (11) : 286B - 287B
  • [8] Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia
    Faderl, Stefan
    Rai, Kanti
    Gribben, John
    Byrd, John C.
    Flinn, Ian W.
    O'Brien, Susan
    Sheng, Shihong
    Esseltine, Dixie-Lee
    Keating, Michael J.
    CANCER, 2006, 107 (05) : 916 - 924
  • [9] Interim analysis of a phase II study of the combination of denileukin diftitox (Ontak) and rituximab for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
    Dang, NH
    McLaughlin, P
    Fayad, L
    Romaguera, J
    Hagemeister, F
    Younes, A
    Neelapu, S
    Samaniego, F
    Jones, D
    Walker, PL
    Rodriguez, MA
    Kwak, L
    Pro, B
    BLOOD, 2005, 106 (11) : 936A - 936A
  • [10] Denileukin diftitox (Ontak®), an interleukin-2 (IL-2) fusion toxin, has significant activity in fludarabine-refractory chronic lymphocytic leukemia (CLL).
    Seymour, JF
    Morgan, SJ
    Wolf, MM
    Prince, HM
    Westerman, DA
    BLOOD, 2003, 102 (11) : 673A - 673A
12345